Newer TKIs Have Received Regulatory Approval as Frontline Treatments for Chronic Myeloid Leukemia
Two newer, more potent tyrosine kinase inhibitors (TKIs) have emerged as frontline treatments for chronic myeloid leukemia (CML), according to research published in Clinical Advances in Hematology & Oncology (H&O).
A rare, slow-growing type of blood cancer, chronic myeloid leukemia originates from the presence of a genetic abnormality in the blood cells. The disease progresses through three distinct phases: chronic (early phase), accelerated (progressive disease) and blast crisis (rapid progression and short survival). Around 85 percent of patients are diagnosed in the chronic phase, when they generally respond well to treatment.
Standard treatment for CML has been the tyrosine kinase inhibitor imatinib (Gleevec/Glivec), first approved in 2001. Since then, the more potent TKIs nilotinib (Tasigna) and dasatinib (Sprycel) have emerged as treatment options for patients who were resistant or intolerant of imatinib.
Research has shown that nilotinib and dasatinib are effective therapies for newly-diagnosed patients, with each slowing progression to advanced CML. Both have received regulatory approval as frontline CML treatments. However, these newer TKIs have different safety profiles that may affect whether a doctor selects either of them as a treatment.
Medify, which has over 6,440 research abstracts on chronic myeloid leukemia alone, is on a mission to provide patients and their loved ones access to the best information online about their medical condition.
- Improving Frontline Treatment for Chronic Myeloid Leukemia: Emerging Evidence for use of Nilotinib and Dasatinib
- What You Should Know: Chronic Myeloid Leukemia
Powered by Facebook Comments